AstraZeneca PLC (AZN)
| Market Cap | 277.49B +26.9% |
| Revenue (ttm) | 60.44B +9.9% |
| Net Income | 10.39B +33.7% |
| EPS | 6.64 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 26.71 |
| Forward PE | 16.98 |
| Dividend | $3.20 (1.79%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 6,648,956 |
| Open | 173.45 |
| Previous Close | 189.28 |
| Day's Range | 172.76 - 180.21 |
| 52-Week Range | 138.00 - 212.71 |
| Beta | 0.23 |
| Analysts | Strong Buy |
| Price Target | 221.09 (+23.87%) |
| Earnings Date | Jul 27, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price target is $221.09, which is an increase of 23.87% from the latest price.
News
AstraZeneca Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into AstraZeneca (AZN)
AstraZeneca (AZN) announced its key CARDIO-TTRansform Phase III trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities claims on behalf of...
AstraZeneca PLC (AZN) Shares Fall 5.7% -- What GF Score of 82 Tells Investors
AstraZeneca PLC (AZN) Shares Fall 5.7% -- What GF Score of 82 Tells Investors
AstraZeneca slump weighs on FTSE 100
AstraZeneca shares fell after trial disappointment, while miners, Computacenter and Playtech supported broader market gains. The post AstraZeneca slump weighs on FTSE 100 appeared first on Investomani...
AstraZeneca in £20bn hit after heart disease drug hoped to be a potential blockbuster flops in trials
Astra's shares tumbled 10.5% after it said its Wainua drug - which it is developing with Ionis - failed to reduce deaths related to heart disease.
AstraZeneca Shares Sink After Heart Drug Trial Miss. Rare Clinical Setback Tests Investor Confidence
AstraZeneca shares fell sharply Thursday after the pharmaceutical giant reported that its experimental use of Wainua failed to achieve the primary endpoint in a late-stage clinical trial for a rare he...
Appeals court upholds win for AstraZeneca in Pfizer patent fight, Reuters says
A U.S. appeals court on Thursday upheld a ruling for AstraZeneca (AZN) against allegations that its blockbuster lung-cancer drug Tagrisso infringed patents owned by Pfizer (PFE) subsidiary Wyeth, Reut...
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight
A U.S. appeals court on Thursday upheld a ruling for AstraZeneca against allegations that its blockbuster lung-cancer drug Tagrisso infringed patents owned by Pfizer subsidiary Wyeth.
AstraZeneca (AZN) Faces Setback as Phase 3 Study Misses Key Endpoint
AstraZeneca (AZN) Faces Setback as Phase 3 Study Misses Key Endpoint
Ionis Pharmaceuticals price target lowered to $94 from $108 at TD Cowen
TD Cowen lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $94 from $108 and keeps a Buy rating on the shares after the company and AstraZeneca’s (AZN) CARDIO-TTRansform…
Is AstraZeneca (AZN) Stock a Buy on Today’s Dip? Here’s What Analysts Have to Say About That
AstraZeneca stock was down on Thursday after it reported a failed clinical trial, but this could present a buying opportunity for investors.
AZN Stock Update: Key Market Insights for Investors
AZN Stock Update: Key Market Insights for Investors
AstraZeneca Slides 9.9% After Heart Drug Trial Misses Late-Stage Goal
AstraZeneca Slides 9.9% After Heart Drug Trial Misses Late-Stage Goal
Morning Movers: Ionis and AstraZeneca sink after trial misses endpoint
Markets are attempting to recover this morning after Wednesday’s geopolitical-driven selloff, with U.S. stock futures moving modestly higher as oil prices retreat from recent highs. Nasdaq futures are...
BridgeBio Pharma (BBIO) and Alnylam Pharma (ALNY) Surge After AstraZeneca Trial Setback
BridgeBio Pharma (BBIO) and Alnylam Pharma (ALNY) Surge After AstraZeneca Trial Setback
Why AstraZeneca Crashed 8%, Leading Three Rivals, Including Pfizer, To Jump
AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing.
5 Things to Know Before the Stock Market Opens on Thursday
Stock futures are slightly higher this morning as investors monitor developments in the Middle East; PepsiCo's results narrowly beat Wall Street estimates as strength in international markets offset s...
UK stocks decline as AstraZeneca tumbles after trial setback
The UK's FTSE 100 declined on Thursday as investors assessed renewed tensions in the Middle East, while pharmaceutical heavyweight AstraZeneca weighed heavily on the benchmark after reporting disappoi...
Stocks making the biggest moves premarket: AstraZeneca, PepsiCo, Salesforce, Levi & more
These are the stocks posting the largest moves in the premarket.
AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.
AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.
London's FTSE 100 slips as Middle East tensions persist, AstraZeneca drags
The UK's FTSE 100 slipped on Thursday as investors grappled with renewed Middle East tensions, with heavyweight AstraZeneca adding to the pressure after reporting disappointing results from a late-sta...
Why Is AstraZeneca Stock (AZN) Falling Today?
AstraZeneca ($AZN) shares fell 9.5% in pre-market trading today after the biotech company said that its experimental heart drug, Wainua (eplontersen), failed to meet the primary endpoint in a late-sta...
AstraZeneca (AZN) Faces Setback in Phase III Cardiomyopathy Trial
AstraZeneca (AZN) Faces Setback in Phase III Cardiomyopathy Trial
AstraZeneca Falls After Wainua Heart Disease Trial Fails
AstraZeneca Falls After Wainua Heart Disease Trial Fails
AstraZeneca (AZN) Shares Plunge Following Trial Setback
AstraZeneca (AZN) Shares Plunge Following Trial Setback
Major drugmaker loses $27 billion in market value after failed trial
Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.